InflaRx (IFRX) Competitors $1.06 +0.01 (+0.95%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.06 0.00 (0.00%) As of 04/17/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IFRX vs. RNAC, TSVT, AQST, TSHA, ATXS, ATYR, ATAI, CMPS, GLUE, and ARCTShould you be buying InflaRx stock or one of its competitors? The main competitors of InflaRx include Cartesian Therapeutics (RNAC), 2seventy bio (TSVT), Aquestive Therapeutics (AQST), Taysha Gene Therapies (TSHA), Astria Therapeutics (ATXS), Atyr PHARMA (ATYR), Atai Life Sciences (ATAI), COMPASS Pathways (CMPS), Monte Rosa Therapeutics (GLUE), and Arcturus Therapeutics (ARCT). These companies are all part of the "pharmaceutical products" industry. InflaRx vs. Cartesian Therapeutics 2seventy bio Aquestive Therapeutics Taysha Gene Therapies Astria Therapeutics Atyr PHARMA Atai Life Sciences COMPASS Pathways Monte Rosa Therapeutics Arcturus Therapeutics InflaRx (NASDAQ:IFRX) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, community ranking, dividends, risk, profitability, analyst recommendations, valuation and media sentiment. Do insiders & institutionals have more ownership in IFRX or RNAC? 42.4% of InflaRx shares are owned by institutional investors. Comparatively, 86.9% of Cartesian Therapeutics shares are owned by institutional investors. 16.3% of InflaRx shares are owned by company insiders. Comparatively, 57.9% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has higher earnings & valuation, IFRX or RNAC? InflaRx has higher earnings, but lower revenue than Cartesian Therapeutics. InflaRx is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInflaRx$165.79K429.23-$46.18M-$0.87-1.22Cartesian Therapeutics$38.91M6.99-$219.71M-$52.83-0.20 Do analysts prefer IFRX or RNAC? InflaRx currently has a consensus price target of $9.00, indicating a potential upside of 749.06%. Cartesian Therapeutics has a consensus price target of $42.14, indicating a potential upside of 301.36%. Given InflaRx's stronger consensus rating and higher possible upside, analysts clearly believe InflaRx is more favorable than Cartesian Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InflaRx 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Cartesian Therapeutics 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the media refer more to IFRX or RNAC? In the previous week, Cartesian Therapeutics had 1 more articles in the media than InflaRx. MarketBeat recorded 2 mentions for Cartesian Therapeutics and 1 mentions for InflaRx. Cartesian Therapeutics' average media sentiment score of 0.30 beat InflaRx's score of -1.00 indicating that Cartesian Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment InflaRx Negative Cartesian Therapeutics Neutral Which has more volatility and risk, IFRX or RNAC? InflaRx has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Is IFRX or RNAC more profitable? Cartesian Therapeutics has a net margin of -510.72% compared to InflaRx's net margin of -33,362.70%. Cartesian Therapeutics' return on equity of 0.00% beat InflaRx's return on equity.Company Net Margins Return on Equity Return on Assets InflaRx-33,362.70% -65.98% -56.86% Cartesian Therapeutics -510.72%N/A -6.03% Does the MarketBeat Community favor IFRX or RNAC? InflaRx received 204 more outperform votes than Cartesian Therapeutics when rated by MarketBeat users. However, 95.00% of users gave Cartesian Therapeutics an outperform vote while only 65.05% of users gave InflaRx an outperform vote. CompanyUnderperformOutperformInflaRxOutperform Votes24265.05% Underperform Votes13034.95% Cartesian TherapeuticsOutperform Votes3895.00% Underperform Votes25.00% SummaryCartesian Therapeutics beats InflaRx on 11 of the 18 factors compared between the two stocks. Get InflaRx News Delivered to You Automatically Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IFRX vs. The Competition Export to ExcelMetricInflaRxPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$71.16M$6.44B$5.29B$7.35BDividend YieldN/A3.23%5.12%4.31%P/E Ratio-0.986.8821.7117.77Price / Sales429.23231.36379.3997.65Price / CashN/A65.6738.2234.64Price / Book0.565.916.443.98Net Income-$46.18M$142.72M$3.21B$247.44M7 Day Performance14.72%4.33%2.81%1.82%1 Month Performance-12.40%-12.80%-8.67%-6.98%1 Year Performance-15.87%-9.71%11.32%1.49% InflaRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IFRXInflaRx1.9941 of 5 stars$1.06+1.0%$9.00+749.1%-16.2%$71.16M$165,789.00-0.9860Short Interest ↑RNACCartesian Therapeutics1.7207 of 5 stars$10.11+1.1%$42.14+316.8%-43.2%$261.92M$38.91M-0.1964TSVT2seventy bio1.9348 of 5 stars$4.95flat$6.67+34.7%-1.6%$259.07M$37.86M-2.66440Short Interest ↓Positive NewsHigh Trading VolumeAQSTAquestive Therapeutics1.8191 of 5 stars$2.62-3.3%$10.57+303.5%-36.0%$259.04M$57.56M-5.82160Gap DownTSHATaysha Gene Therapies2.6728 of 5 stars$1.24+1.6%$6.63+434.3%-49.4%$254.20M$8.33M1.97180ATXSAstria Therapeutics2.4671 of 5 stars$4.50-3.4%$26.60+491.1%-61.7%$253.95MN/A-2.1530Gap DownATYRAtyr PHARMA2.5929 of 5 stars$2.85+8.8%$18.60+552.6%N/A$253.25M$235,000.00-3.0353Positive NewsATAIAtai Life Sciences1.8705 of 5 stars$1.27-3.1%$10.50+726.8%-25.8%$251.85M$308,000.00-1.5780CMPSCOMPASS Pathways2.5401 of 5 stars$2.70-0.4%$20.20+648.1%-63.3%$250.22MN/A-1.23120News CoverageGLUEMonte Rosa Therapeutics3.1171 of 5 stars$4.05+2.5%$15.50+282.7%-21.6%$249.12M$75.62M-2.2190Short Interest ↓Positive NewsARCTArcturus Therapeutics2.7812 of 5 stars$9.09-0.2%$59.20+551.3%-61.9%$246.52M$138.39M-4.09180 Related Companies and Tools Related Companies Cartesian Therapeutics Competitors 2seventy bio Competitors Aquestive Therapeutics Competitors Taysha Gene Therapies Competitors Astria Therapeutics Competitors Atyr PHARMA Competitors Atai Life Sciences Competitors COMPASS Pathways Competitors Monte Rosa Therapeutics Competitors Arcturus Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IFRX) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThey Won’t Tell You This About GoldInflation, digital currency, and government policy are quietly eating away at your savings — and most people w...American Alternative | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InflaRx Please log in to your account or sign up in order to add this asset to your watchlist. Share InflaRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IFRX Stock Free IFRX Stock Alerts